Developing Innovative Therapeutics for Ocular Diseases

Global leading candidate in Phase 2b for the treatment of adenoviral conjunctivitis.

Enhancing Lives Through Better Vision

Okogen, founded in 2015, is a clinical stage ophthalmic specialty biotechnology company. We are exclusively focused on developing the leading treatment of adenoviral conjunctivitis.

With acute conjunctivitis representing 1% of all primary care visits in the US, we see a significant need and opportunity.